Foresee Pharma out-licenses FP-001 program

11 February 2019

Accord Healthcare, a UK-based subsidiary of Indian biopharma company Intas Pharmaceuticals, has been granted the rights to a novel FP-001 program (leuprorelin depot), leuprolide mesylate injectables (LMIS) ready-to-use subcutaneous depot formulations by Foresee Pharmaceutical (6576. TWO).

Under the terms of this partnership, Foresee, a Taiwan and USA based biopharmaceutical company, will receive a combination of upfront, regulatory milestones and sales milestones payments totalling up to$ 86 million in addition to a significant share of the product revenue in the territory. Accord Healthcare will cover all costs of commercialisation in the territory. Despite the news, Foresee’s shares fell 4.47% to 66.30 won by close of trading today.

The license agreement will cover the global market with the exception of the USA, mainland China, Japan, Taiwan and previously partnered territories,Israel, Turkey and certain Middle East countries. Rights to the program for Turkey and the Middle East markets were granted to TRPharm in 2017.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK